血清sCD30和sCD40水平与弥漫大B细胞淋巴瘤临床病理特征的关系  

Relationships between the level of sCD30 and sCD40 in serum and clinicopathological features of diffuse large B-cell lymphoma

作　　者：赵菲[1] 朱芳[2] 刘婷[3] ZHAO Fei;ZHU Fang;LIU Ting(Department of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan Hubei 430000,China;Department of Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan Hubei 430000,China;Department of Infectious Diseases,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan Hubei 430000,China)

机构地区：[1]华中科技大学同济医学院附属协和医院血液科,湖北武汉430000 [2]华中科技大学同济医学院附属协和医院肿瘤中心,湖北武汉430000 [3]华中科技大学同济医学院附属协和医院感染科,湖北武汉430000

出　　处：《临床和实验医学杂志》2020年第18期1916-1919,共4页Journal of Clinical and Experimental Medicine

基　　金：国家青年科技基金项目(编号:81101789)。

摘　　要：目的探究血清可溶性CD30(sCD30)、可溶性CD40(sCD40)表达与弥漫大B细胞淋巴瘤(DLBCL)临床病理特征的关系。方法选取2011年1月至2013年10月华中科技大学同济医学院附属协和医院收治的DLBCL患者86例作为DLBCL组,另选择60例健康体检者为对照组,采用酶联免疫吸附试验测定两组患者血清中sCD30、sCD40表达水平;分析与临床病理特征之间的关系;采用Cox多因素回归分析影响DLBCL预后的因素。结果DLBCL组患者血清中sCD30、sCD40表达水平分别为(51.34±10.42)ng/ml、(16.79±3.45)ng/ml,均高于对照组(5.68±1.13)ng/ml、(3.13±0.34)ng/ml(P<0.05);与I期比较[(45.32±6.33)ng/ml、(13.24±1.57)ng/ml],III[(50.23±5.29)ng/ml]、Ⅳ期[(54.45±9.81)ng/ml]DLBCL患者sCD30水平依次升高,II[(14.39±1.25)ng/ml]、III[(15.78±2.39)ng/ml]、Ⅳ期[(18.56±3.79)ng/ml]DLBCL患者sCD40水平依次升高(P<0.05);sCD30、sCD40表达水平与DLBCL患者年龄、临床分期、IPI评分有关(P<0.05),与性别、Hans分型、B症状及起病部位无关(P>0.05);sCD30、sCD40高表达组DLBCL患者的5年生存率分别为13.89%、17.65%,显著低于sCD30(76.32%)、sCD40(80.00%)低表达组(P<0.05);Cox多因素回归分析结果显示,临床分期、IPI评分、sCD30及sCD40表达水平是影响DLBCL患者预后的独立危险因素(HR=1.432,95%CI:1.241~1.652;HR=1.357,95%CI:1.218~1.512;HR=2.654,95%CI:1.957~3.599;HR=4.129,95%CI:2.382~7.157)。结论sCD30、sCD40在DLBCL患者显著高表达,与患者年龄、临床分期、IPI评分及5年生存率有关,是影响患者预后的独立危险因素,检测血清sCD30、sCD40水平对研究DLBCL临床病理及判断预后有一定参考价值。Objective To explore the relationships between the expressions of sCD30 and sCD40 in serum and the clinicopathological features of diffuse large B-cell lymphoma(DLBCL).Methods 86 patients with diffuse large B-cell lymphoma who were first diagnosed in Union Hospital,Tongji Medical College,Huazhong University of Science and Technology were selected as DLBCL group,and another 60 healthy people were selected as control group.The levels of serum sCD30 and sCD40 were measured by enzyme-linked immunosorbent assay,the relationship between analysis and clinicopathological features,and Cox multivariate regression analysis was used to analyze the prognostic factors of DLBCL.Results The expression levels of sCD30 and sCD40 in serum of DLBCL group were(51.34±10.42)ng/ml and(16.79±3.45)ng/ml,higher than that in control group(5.68±1.13)ng/ml and(3.13±0.34)ng/ml(P<0.05).Compared with stage I(45.32±6.33)ng/ml and(13.24±1.57)ng/ml,the level of sCD30 was increased successively in stage III[(50.23±5.29)ng/ml]andⅣ[(54.45±9.81)ng/ml]DLBCL patients,and the level of sCD40 was significantly increased successively in stage II[(14.39±1.25)ng/ml],III[(15.78±2.39)ng/ml]andⅣ[(18.56±3.79)ng/ml]DLBCL patients(P<0.05).The levels of sCD30 and sCD40 were correlated with age,pathological stage,IPI score of DLBCL patients(P<0.05),but not with sex,Hans type,B symptom and the site of onset(P>0.05).The 5-year survival rates of DLBCL patients with high expressions of sCD30 and sCD40 were 13.89%and 17.65%,significantly lower than those with low expressions of sCD30(76.32%)and sCD40(80.00%)(P<0.05).Cox regression results showed that clinical stage,IPI score,and the expressions of sCD30 and sCD40 were independent risk factors for prognosis of DLBCL patients(HR=1.432,95%CI:1.241~1.652;HR=1.357,95%CI:1.218~1.512;HR=2.654,95%CI:1.957-3.599;HR=4.129,95%CI:2.382~7.157).Conclusion SCD30 and sCD40 are highly expressed in serum of DLBCL patients,which are related to age,pathological stage,IPI score and 5-year survival rate.They are independent risk

关 键 词：弥漫大B细胞淋巴瘤 可溶性CD30 可溶性CD40 临床病理特征 

分 类 号：R733.1[医药卫生—肿瘤]